

The Complete Genome Sequence of the Emerging Pathogen *Mycobacterium haemophilum* Explains Its Unique Culture Requirements

JoAnn M. Tufariello,^{a,b} Christopher A. Kerantzas,^a Catherine Vilchère,^{a,c} R. Brent Calder,^d Eric K. Nordberg,^e Jack A. Fischer,^a Travis E. Hartman,^a Eva Yang,^a Timothy Driscoll,^f Laura E. Cole,^a Robert Sebra,^g Shahina B. Maqbool,^h Alice R. Wattam,^e William R. Jacobs, Jr.^{a,c}

Department of Microbiology and Immunology,^a Department of Medicine,^b and Howard Hughes Medical Institute,^c Division of Computational Genetics and Department of Genetics,^d Albert Einstein College of Medicine, Bronx, New York, USA; Virginia Bioinformatics Institute, Virginia Tech University, Blacksburg, Virginia, USA^e; Department of Biology (Microbial Metagenomics), West Virginia University, Morgantown, Virginia, USA^f; Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, New York, USA^g; Epigenomics Shared Facility, Albert Einstein College of Medicine, Bronx, New York, USA^h

ABSTRACT *Mycobacterium haemophilum* is an emerging pathogen associated with a variety of clinical syndromes, most commonly skin infections in immunocompromised individuals. *M. haemophilum* exhibits a unique requirement for iron supplementation to support its growth in culture, but the basis for this property and how it may shape pathogenesis is unclear. Using a combination of Illumina, PacBio, and Sanger sequencing, the complete genome sequence of *M. haemophilum* was determined. Guided by this sequence, experiments were performed to define the basis for the unique growth requirements of *M. haemophilum*. We found that *M. haemophilum*, unlike many other mycobacteria, is unable to synthesize iron-binding siderophores known as mycobactins or to utilize ferri-mycobactins to support growth. These differences correlate with the absence of genes associated with mycobactin synthesis, secretion, and uptake. In agreement with the ability of heme to promote growth, we identified genes encoding heme uptake machinery. Consistent with its propensity to infect the skin, we show at the whole-genome level the genetic closeness of *M. haemophilum* with *Mycobacterium leprae*, an organism which cannot be cultivated *in vitro*, and we identify genes uniquely shared by these organisms. Finally, we identify means to express foreign genes in *M. haemophilum*. These data explain the unique culture requirements for this important pathogen, provide a foundation upon which the genome sequence can be exploited to improve diagnostics and therapeutics, and suggest use of *M. haemophilum* as a tool to elucidate functions of genes shared with *M. leprae*.

IMPORTANCE *Mycobacterium haemophilum* is an emerging pathogen with an unknown natural reservoir that exhibits unique requirements for iron supplementation to grow *in vitro*. Understanding the basis for this iron requirement is important because it is fundamental to isolation of the organism from clinical samples and environmental sources. Defining the molecular basis for *M. haemophilum*'s growth requirements will also shed new light on mycobacterial strategies to acquire iron and can be exploited to define how differences in such strategies influence pathogenesis. Here, through a combination of sequencing and experimental approaches, we explain the basis for the iron requirement. We further demonstrate the genetic closeness of *M. haemophilum* and *Mycobacterium leprae*, the causative agent of leprosy which cannot be cultured *in vitro*, and we demonstrate methods to genetically manipulate *M. haemophilum*. These findings pave the way for the use of *M. haemophilum* as a model to elucidate functions of genes shared with *M. leprae*.

Received 5 August 2015 Accepted 7 October 2015 Published 17 November 2015

Citation Tufariello JM, Kerantzas CA, Vilchère C, Calder RB, Nordberg EK, Fischer JA, Hartman TE, Yang E, Driscoll T, Cole LE, Sebra R, Maqbool SB, Wattam AR, Jacobs WR, Jr. 2015. The complete genome sequence of the emerging pathogen *Mycobacterium haemophilum* explains its unique culture requirements. *mBio* 6(6):e01313-15. doi:10.1128/mBio.01313-15.

Editor Eric J. Rubin, Harvard School of Public Health

Copyright © 2015 Tufariello et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license](https://creativecommons.org/licenses/by-nc-sa/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address correspondence to William R. Jacobs, jacobsw@hhmi.org, or JoAnn M. Tufariello, joann.tufariello@einstein.yu.edu.

This article is a direct contribution from a Fellow of the American Academy of Microbiology.

Mycobacterium haemophilum is a slow-growing acid-fast bacterium of the nontuberculous mycobacteria group that prefers a lower temperature for growth (30°C to 32°C) and requires iron supplementation, typically either hemin or high concentrations of ferric ammonium citrate, for its growth (1–3). Like other mycobacterial species that grow optimally at lower temperatures, such as *Mycobacterium marinum* and *Mycobacterium ulcerans*,

M. haemophilum is most associated with cutaneous infections of the extremities (1, 4). Less common clinical manifestations of *M. haemophilum* infection include skeletal infections, such as osteomyelitis and septic arthritis, pulmonary infections, ophthalmologic involvement, and disseminated disease (1, 5–11). These cutaneous and extracutaneous manifestations occur primarily in the setting of severe immune compromise (12). Some case reports

have also described a leprosy-like presentation of *M. haemophilum* in immunocompromised individuals (13, 14). *M. haemophilum* has also been reported to cause cervicofacial lymphadenitis in immunocompetent children (15) and adults (16).

Infection with *M. haemophilum* occurs worldwide and, although it has been until now an infrequently isolated pathogen, the incidence appears to be rising since its initial discovery in 1978 (2). This likely reflects the emergence of severe immune compromise due to HIV/AIDS or in the settings of bone marrow/solid organ transplantation, hematologic malignancy, or treatment with disease-modifying agents for rheumatologic disorders (8, 12, 17–22), all of which predispose to infection with this opportunistic pathogen. At present there is no standardized protocol for *in vitro* susceptibility testing (1), although recommendations for a disk agar elution method for *M. haemophilum* are included in a recent Clinical and Laboratory Standards Institute (CLSI) document (23). Further, it is unknown how predictive the results are of clinical outcomes. Optimal treatment regimens also remain undefined (1); however, there is a general consensus that patients should receive a combination of agents that appear to be active *in vitro*, such as clarithromycin, ciprofloxacin, and a rifamycin, for a prolonged duration (~12 to 24 months) which is tailored to the individual's presentation and degree of immune compromise (1, 12, 24, 25). For immunocompetent patients with lymph node involvement, surgical excision may be sufficient (1, 12). The natural habitat/reservoir of *M. haemophilum* as well as its mode of transmission also remain poorly defined. While many nontuberculous mycobacteria are found in soil and aquatic habitats, attempts to recover *M. haemophilum* from environmental samples have often proven unsuccessful, although this may be attributed in part to the slow growth of the organism and its fastidious growth requirements (1).

Very little genetic information has been available for *M. haemophilum*. This limits understanding of its unique growth requirements and how these properties shape its pathogenesis. We therefore determined the complete genome sequence of the *M. haemophilum* DSM 44634 type strain and performed accompanying experiments that implicated the absence of mycobactin synthesis machinery, which in other mycobacteria plays a critical role in iron acquisition, as a major factor in the iron dependence of this organism. Further analysis demonstrated a close evolutionary relationship with *Mycobacterium leprae* and identified both genetic features conserved with other mycobacteria and also unique features that reflect the specific biology of this emerging pathogen. The data also provide groundwork for the development of improved diagnostic tests that will facilitate understanding of the pathogenesis, epidemiology, and mode of transmission of this emerging pathogen. Finally, as a first step toward experimental use of this genetic information, we identify means to introduce and express foreign genetic material in *M. haemophilum*, which should allow exploitation of this organism as a means to study gene products uniquely shared with *M. leprae*.

RESULTS AND DISCUSSION

***In vitro* growth phenotypes.** *M. haemophilum* requires iron supplementation for its growth. We explored the effect of different iron sources by propagating *M. haemophilum* in heme-containing 7H9 liquid medium and then washing and plating the bacteria onto various solid media. Unable to grow on oleic acid-albumin-dextrose-catalase (OADC)-enriched Middlebrook 7H10 agar




FIG 1 *M. haemophilum* growth is supported by hemin and hemoglobin, but not by mycobactin or carboxymycobactin. (A) *M. haemophilum* was plated onto 7H10 medium without supplement; 7H10 medium supplemented with 100 μM hemin, 2 μg/ml mycobactin J (MbJ), or 100 μM human hemoglobin (Hg); or 5% sheep blood agar or chocolate agar. Photographs were taken after ~8 weeks of incubation at 30°C. (B) Growth of *M. haemophilum*, *M. tuberculosis* strain mc²6230, or *M. tuberculosis* strain mc²6230 with deletion of the *mbtB* gene ($\Delta mbtB$) on 7H10 medium containing 24 μg/ml pantothenate (pan) and without further supplement, or supplemented with the indicated concentrations of hemin, MbJ, or *M. smegmatis* carboxymycobactin (cMb).

without other supplements, *M. haemophilum* grew well on 7H10 medium containing 100 μM hemin (Fig. 1A). Growth was also well-supported on 7H10 agar supplemented with human hemoglobin and on 5% sheep blood agar. Growth was somewhat less abundant on chocolate agar (in which blood cells have been lysed by heating) (Fig. 1A). These data are consistent with prior observations (2, 5, 26, 27).

Mycobacterium tuberculosis and other mycobacteria produce siderophores, small iron-chelating compounds, termed mycobactins and carboxymycobactins, which bind and facilitate uptake of environmental ferric iron (Fe^{3+}). In one prior report, several *M. haemophilum* clinical isolates failed to grow on Lowenstein-Jensen (LJ) medium supplemented with mycobactin at 2 μg/ml (28), but earlier studies on one of the same isolates (prior to its identification as *M. haemophilum*) reported that mycobactin did support growth (29). We observed that *M. haemophilum* failed to form colonies on 7H10 agar supplemented with 2 μg/ml mycobactin J (from *Mycobacterium avium* subsp. *paratuberculosis*), but it did form colonies with 100 μM hemin (Fig. 1A). We also compared the growth properties of *M. haemophilum* with mc²6230, an *M. tuberculosis* H37Rv $\Delta RD1 \Delta panCD$ auxotrophic strain that

requires pantothenate supplementation (7H10-pan) and can be used under biosafety level 2 (BSL2) containment (30, 31), with those of a $\Delta mbtB$ mutant strain generated in the mc²6230 background which lacks an essential component of the mycobactin synthesis pathway (32). Whereas mc²6230 grew well under all conditions tested, the $\Delta mbtB$ mutant failed to grow on 7H10-pan but did grow on 7H10-pan supplemented with 100 μ M hemin, 2 μ g/ml mycobactin J, and 200 ng/ml *M. smegmatis* carboxymycobactin (Fig. 1B). In contrast, *M. haemophilum* was unable to grow with either mycobactin J or carboxymycobactin supplementation, although again, growth was abundant on 100 μ M hemin (Fig. 1B). These results suggest a defect(s) in the uptake and/or utilization of siderophore-bound iron by *M. haemophilum*.

In several experiments, inoculation of *M. haemophilum* onto 7H10 medium supplemented with 15 mg/ml ferric ammonium citrate (FAC) resulted in absent or very suboptimal growth (data not shown). Others have observed growth of *M. haemophilum* on LJ medium supplemented with 15 mg/ml FAC but not on 7H10 medium with the same concentration of FAC (28, 33). Conversely, although 7H10 supplemented with hemin supports growth, it has been observed that LJ with hemin does not (27, 28, 33). These findings suggest that interactions occur between particular iron complexes and other components of the media.

Overview of the *M. haemophilum* genome. To gain further insights into its growth requirements, the complete *M. haemophilum* genome sequence was determined. The genome consists of a single circular chromosome of 4,235,765 bp with an average GC content of 63.9% and encodes an estimated 3,964 genes (NCBI Prokaryotic Genome Annotation Pipeline). Pertinent characteristics of the genome in comparison with other mycobacterial species are listed in Table S1 in the supplemental material. Functional assignments using database comparisons were obtained for approximately two-thirds of coding sequences, with the remainder encoding hypothetical proteins (Rapid Annotation Using Subsystem Technology, or RAST [National Microbial Pathogen Data Resource]). Gene numbers referred to in the text are those assigned by RAST under Genome ID 1202450.9. A representation of the *M. haemophilum* chromosome is shown in Fig. 2, including the orientation of the coding sequences, percent GC content, and GC skew.

Mycobactin synthesis: *mbt-1* (*mbtA-mbtJ*) gene cluster. In *M. tuberculosis*, the salicylate-based mycobactin siderophores are synthesized by enzymes encoded in two distinct gene clusters, *mbt-1* (*mbtA-mbtJ*) and *mbt-2* (*mbtK-mbtN*) (34, 35). One striking feature of the *M. haemophilum* genome is the absence of close homologues of almost all of the 14 genes comprising these two mycobactin synthesis clusters (Fig. 3A and B). For the *mbtA-mbtJ* cluster, close homologues of 7 of the 10 genes—*mbtG*, *mbtF*, *mbtE*, *mbtD*, *mbtC*, *mbtB*, and *mbtA*—appear to be missing in *M. haemophilum* (Fig. 3A). An open reading frame (ORF) encoding a putative protein with significant homology to MbtH, found at one end of the *mbtA-mbtJ* locus in H37Rv, does appear to be present [with 78% identity to H37Rv MbtH (Rv2377c) over 71 amino acids]. However, the product of this gene may not function in mycobactin synthesis, as homologues in other bacteria, such as actinomycetes and a rapid-growing mycobacterium, *Mycobacterium smegmatis*, have been implicated in other pathways, such as synthesis of cell wall glycopeptidolipids (36–38).

For the remainder of the *mbt-1* gene cluster, close homologues of *mbtJ* and *mbtI*, found at the opposite end of the H37Rv gene

cluster, are also present in *M. haemophilum* (Fig. 3A). However, the *M. haemophilum* *mbtJ* and *mbtI* homologues are in a locus physically distant from the *mbtH* homologue, separated by greater than 600 kb. MbtJ is a putative acetyl hydrolase whose precise role in mycobactin synthesis remains unclear (35). MbtI, the first enzyme in the mycobactin synthesis pathway, is a salicylate synthase (39). *M. haemophilum* does not possess a full-length *mbtI* gene but does contain an open reading frame encoding a product with homology to the C-terminal portion of MbtI (88% identity to the C-terminal 100 amino acids of the H37Rv MbtI). This region also shares homology with TrpE (anthranilate synthase, which catalyzes the first committed step in tryptophan biosynthesis) and other enzymes which act on chorismate in a variety of metabolic pathways (39). Therefore, this gene might participate in a different metabolic pathway.

Mycobactin synthesis: *mbt-2* (*mbtK-mbtN*) gene cluster. Although *M. tuberculosis* *mbt-1* encodes enzymes necessary for synthesis of the mycobactin backbone, it lacks genes encoding enzymes that attach the fatty acyl chain. These components of the siderophore biosynthetic machinery lie within the *mbt-2* (*mbtK-mbtN*) gene cluster (34). The entire *mbt-2* gene cluster appears to be absent in *M. haemophilum* (Fig. 3B). Together with the absence of *mbtG*, *mbtF*, *mbtE*, *mbtD*, *mbtC*, *mbtB*, and *mbtA* homologues, the absence of all four genes comprising the *mbt-2* cluster makes it highly unlikely that *M. haemophilum* is capable of synthesizing mycobactin siderophores. Interestingly, the only mycobacterial species with similarly extensive deletions of the *mbt-1* and *mbt-2* regions are *M. leprae* (40) and the recently identified and closely related *M. lepromatosis* (41, 42), both of which have genomes characterized by extreme reductive evolution.

Functional analysis of mycobactin synthesis. To experimentally address production of mycobactin or carboxymycobactin by *M. haemophilum*, we cultured the bacteria under iron-replete conditions followed by transfer to iron-limited medium containing the radiolabeled mycobactin precursor [7-¹⁴C]salicylic acid. The iron-limited medium should, based on data from *M. tuberculosis* (43), increase expression of the mycobactin synthesis machinery. *M. tuberculosis* mc²6230, which has intact mycobactin synthesis, secretion, and uptake systems, was grown under similar conditions and served as a control. We tested two growth conditions: chelated 7H9 (see the supplemental text describing further materials and methods) in the presence and absence of 10 μ M hemin. We expected that the latter might afford better growth while still imposing iron restriction. Cell-associated and secreted siderophores extracted from cell pellets and culture filtrates were analyzed by thin-layer chromatography (TLC). Because *M. haemophilum* failed to grow as well as mc²6230 in the iron-limited medium, even with the addition of 10 μ M hemin, the two *M. haemophilum* cultures were pooled for siderophore extraction. TLC analysis revealed an absence of mycobactin or carboxymycobactin production by *M. haemophilum* under the growth conditions tested, in either the cell pellet or the culture supernatant (Fig. 4). For mc²6230, both mycobactin and carboxymycobactin were present in the cell pellet, with smaller amounts in the culture supernatant. These findings are the first direct evidence for lack of mycobactin/carboxymycobactin production by *M. haemophilum*. Due to relatively poor growth of *M. haemophilum* compared with mc²6230 in the iron-limited medium, a significantly smaller cell mass was analyzed; however, despite equal radioactive label on material being run on the TLC, there was still a complete absence




FIG 2 Circular representation of the *M. haemophilum* chromosome. Concentric rings, numbered from outer to inner rings, show the following: 1, scale (in megabases) starting at the top center and running clockwise; 2, forward coding sequences (CDS), in dark green; 3, reverse CDS, in light green; 4, GC content (percentage) as a line plot, with axes from 20% (inner) to 80% (outer), with lines every 15%, where the dark orange background indicates a GC content above 50%; 5, GC skew of genes as a line plot symmetrical about a skew of 1. The plot was generated using the CIRCOS circular genome data visualization program and the genome sequence as submitted for annotation by RAST.

of mycobactin and carboxymycobactin detected in the *M. haemophilum* samples, and the only radiolabeled species associated with the cell pellet was [^{14}C]salicylate. The suboptimal growth of *M. haemophilum* in iron-limited medium is, in itself, consistent with a lack of siderophore production by the strain. The *M. haemophilum* genome, like that of *M. tuberculosis*, appears to lack a gene cluster homologous to that present in the rapid-growing

M. smegmatis which encodes the synthesis of the non-salicylate-containing peptidic exochelin siderophores (44–46); however, the possibility that *M. haemophilum* synthesizes an alternative siderophore is not excluded.

Mycobactin uptake and secretion: IrtA/B and MmpL/MmpS proteins. Adjacent to the *mbt-2* gene cluster in *M. tuberculosis* H37Rv are the iron-regulated transporter A (*irtA*; Rv1348) and




FIG 3 Comparison of *mbt-1* and *mbt-2* gene clusters in *M. tuberculosis* and *M. haemophilum*. (A) *M. haemophilum* lacks major portions of mycobactin synthesis cluster 1 (*mbt-1*). The *M. haemophilum* genomic region corresponding to *mbt-1* was compared to the analogous region of *M. tuberculosis* H37Rv. Genes of the *mbt-1* cluster are shown on a background of yellow shading. Scale bar, 1,000 nucleotides (nt). (B) *M. haemophilum* lacks the entirety of mycobactin synthesis cluster 2 (*mbt-2*) and adjacent *irtA-irtB*. The *M. haemophilum* genomic region corresponding to *mbt-2* was compared to the analogous regions of *M. tuberculosis* H37Rv and *M. leprae*. Genes of the *mbt-2* cluster are shown on a background of yellow shading. Scale bar, 500 nt. In panels A and B, arrows indicate genes and gene orientation, while arrow colors indicate functional roles of the genes, according to the key at the bottom of the diagram. Conserved genes flanking the *mbt-1* and *mbt-2* loci are on a background of purple shading.

irtB (Rv1349) genes, which are cotranscribed (47) and, along with the *mbt-1* and *mbt-2* clusters, are part of the IdeR regulon, with their transcription repressed under iron-replete conditions (43, 48). *irtA* and *irtB* appear to encode an ABC transporter which participates in the uptake and utilization of siderophore-bound iron and enables growth under iron-deficient conditions (49). Homologues of *irtA* and *irtB* are lacking in *M. haemophilum* (Fig. 3B), again similar to *M. leprae*.

Recently, members of the mycobacterial membrane protein large (MmpL) and small (MmpS) families have been found to play a role in the secretion of mycobacterial siderophores (50). *M. haemophilum* encodes close counterparts of MmpL4 (Mh0573) and MmpS4 (Mh0574), located immediately adjacent to one another. However, although there are additional *mmpL* and *mmpS* genes,

we were unable to identify equally close homologues of MmpL5 and MmpS5, which contribute to siderophore synthesis and secretion in *M. tuberculosis* (50). Notably, MmpS4 is also required for export of cell surface glycopeptidolipids in *M. smegmatis* (51). Therefore, *M. haemophilum* MmpS4/MmpL4 homologues may participate in transport of substances other than mycobactins.

Heme uptake, utilization, and biosynthesis. Recently, a heme acquisition system involving a secreted heme-binding protein (Rv0203) and the transmembrane proteins MmpL11 (Rv0202c) and MmpL3 (Rv0206c) was identified for *M. tuberculosis* (52). *M. haemophilum* encodes homologues of Rv0203 (Mh0273), MmpL11 (Mh0272), and MmpL3 (Mh0276), located in close proximity to one another, similar to their counterparts in H37Rv. *M. haemophilum* also encodes a homologue (Mh3902) of the




FIG 4 *M. haemophilum* does not produce mycobactin. Synthesis and release of mycobactin was assessed by culturing *M. tuberculosis* strain mc²6230 or *M. haemophilum* in iron-deficient media, conditions that induced mycobactin synthesis for *M. tuberculosis*. [¹⁴C]salicylate was added to cultures to label newly synthesized mycobactin, and extracts of bacterial pellets and culture supernatants were analyzed by TLC by loading equal activity (counts per minute). Lane 1, mc²6230 cell pellet; lane 2, *M. haemophilum* cell pellet; lane 3, mc²6230 supernatant; lane 4, *M. haemophilum* supernatant; lane 5, [¹⁴C]salicylate. Indicated are the expected locations of mycobactin (Mb) and carboxymycobactin (cMb) from *M. smegmatis*, based on migration of purified nonradioactive standards (data not shown).

M. tuberculosis MhuD (mycobacterial heme utilization, degrader; Rv3592), which binds to and degrades heme (53). Therefore, our genome sequence data reveal intact heme uptake and utilization systems in *M. haemophilum*, in agreement with the results of the growth studies reported here. This in contrast to *M. leprae*, which, although it encodes homologues of MmpL11 and MmpL3, appears to lack a counterpart to the secreted heme-binding protein Rv0203 (40), suggesting a possible deficiency in the scavenging of heme-iron. *M. haemophilum* also appears to possess close homologues of *M. tuberculosis* H37Rv genes that encode putative heme biosynthetic pathway components (see Table S2 in the supplemental material), and again this differs from *M. leprae*, which is missing the *hemN* gene (42), and therefore may be impaired in heme biosynthesis.

ESX loci including ESX-3. Type VII secretion systems (T7SSs) encoded within ESX loci permit transport of proteins across the lipid-rich cell envelope to the cell surface or external environment. The ESX loci are large gene clusters which code for the ATP-dependent secretory apparatuses needed to export members of the 6-kDa early secretory antigenic target (ESAT-6)/culture filtrate protein 10 (CFP-10) protein families (EsxA/EsxB of the ESX-1 region and their paralogues), as well as a number of additional/associated substrates which remain to be fully defined. *M. tuberculosis* possesses five ESX systems, encoded within gene clusters designated ESX-1 to ESX-5, several of which play important roles in *M. tuberculosis* pathogenesis and intracellular survival (54). *M. haemophilum* possesses homologues of all five ESX systems (see Table S3 in the supplemental material).

The ESX-3 locus of *M. haemophilum* is of particular interest, because it has been implicated in iron and zinc homeostasis in *M. tuberculosis* (55–57). *M. tuberculosis* *esx-3* expression is regulated by the availability of iron and zinc, under control of both the IdeR repressor and the zinc uptake regulator Zur/FurB (Rv2359) (58). ESX-3 is likely necessary for the uptake and/or utilization of iron bound to mycobactin (57), although involvement in alternative mycobacterial metal ion uptake processes has also been suggested (59, 60). The absence of genes required for mycobactin synthesis and mycobactin uptake/export in *M. haemophilum* makes a largely intact ESX-3 locus in *M. haemophilum* noteworthy (Fig. 5). Of the 11 ORFs in the *M. tuberculosis* ESX-3 region, 10 have close homologues in the corresponding region of *M. haemophilum*, including genes encoding both EsxG and EsxH, which are believed to be secreted as a heterodimeric complex (57, 61), similar to the EsxA-EsxB secreted effectors of the ESX-1 region.

All ESX loci with the exception of the smallest and most archaic, ESX-4, possess a *pe-pe* gene pair adjacent to the *esx* gene pair (54); these are named for the conserved proline-glutamic acid (PE) and proline-proline-glutamic acid (PPE) residues found near the N termini of the encoded proteins. The only gene which is absent from its expected location within the ESX-3 region of *M. haemophilum* is *ppe4* (Rv0286), the *ppe* component of the *pe-pe* pair present within the *M. tuberculosis* H37Rv ESX-3 locus (Fig. 5). The significance of this absence with regard to the iron-dependent growth phenotype of the organism and the inability of mycobactin to support growth (Fig. 1A and B) is unclear, because the functions of the *pe* and *ppe* gene families remain largely obscure. It is possible that this deficiency is compensated by *ppe* homologues encoded elsewhere in the genome. Notably, *M. haemophilum* does possess a *ppe* gene immediately upstream of the ESX-3 locus.

Although the *M. haemophilum* genome shares with *M. tuberculosis* the presence of five ESX loci, there are some differences from the corresponding *M. tuberculosis* ESX regions. The primary difference is that several of the *pe* and *ppe* genes are absent from *M. haemophilum*, such as an absent *pe35* homologue within the ESX-1 locus and an absent *ppe4* in the ESX-3 locus, although some of the regions differ in other respects as well (see Table S3 in the supplemental material). For ESX-2, homologues of all 12 of the corresponding *M. tuberculosis* genes are present, but the region is discontinuous, similar to findings for *M. avium* subsp. *paratuberculosis* (62).

Genes present in *M. haemophilum* but absent from *M. tuberculosis* H37Rv that may be related to iron acquisition. Comparison of the *M. haemophilum* genome with other mycobacterial species revealed a number of genes present in *M. haemophilum* but absent from *M. tuberculosis* H37Rv. These included several genes with potential roles in iron acquisition. One, Mh1776, is annotated as ferrous iron transport protein B (*feoB*) and encodes a protein with significant homology to an integral component of the Feo inner membrane transport system, which functions in the uptake of ferrous (Fe²⁺) iron (63, 64). Although this system has been best studied in enteric Gram-negative bacteria such as *Escherichia coli* and *Salmonella* species (65, 66), genes encoding the Feo system have been identified in more than 40% of sequenced bacterial genomes (64).

In *E. coli*, the Feo system contains three genes encoded in the locus *feoABC*; although in other bacterial genomes, *feoC* is often absent (64). This is the situation for *M. haemophilum*, which con-




FIG 5 Comparison of *esx-3* loci from *M. haemophilum*, *M. tuberculosis*, and *M. leprae*. The *M. haemophilum* *esx-3* genomic region was compared to the analogous regions of *M. tuberculosis* H37Rv and *M. leprae*. Genes of the *esx-3* cluster are shown on a background of yellow shading. Conserved genes flanking the *esx-3* locus are on a background of purple shading. Arrows indicate genes and gene orientations. Arrow colors indicate functional roles of the genes, according to the key at the bottom of the diagram. Scale bar, 1,000 nucleotides (nt).

tains adjacent *feoA* (Mh1777) and *feoB* (Mh1776) genes, but has no obvious *feoC* paralogue. Ferrous iron is thought to be transported across the cytoplasmic membrane by the GTP-dependent permease FeoB (67). The small hydrophilic FeoA protein appears to interact with FeoB and to be required for transport (68). The presence of FeoA and FeoB suggests that *M. haemophilum* may encounter conditions (anaerobic and/or acidic) in its *in vivo* niche that increase the availability of ferrous iron, or perhaps that the bacterium is capable of reducing extracellular ferric ions to promote uptake by this system. Although absent in *M. tuberculosis* and *M. leprae*, BLAST analysis identifies homologues of FeoA and FeoB in a number of nontuberculous mycobacteria, including *M. kansasii*, *M. marinum*, *M. genavense*, and *M. xenopi*.

M. haemophilum also possesses a second natural resistance-associated macrophage protein (Nramp) family member. Nramps were initially identified in eukaryotes as integral membrane proteins that function as pH-dependent high-affinity divalent metal ion transporters (69–71). Many bacteria also possess Nramp family members (72, 73), including *M. tuberculosis*, which has a single homologue (74–76). This is in contrast to *M. leprae* which, even with its small genome size, bears two copies of a *mntH/nramp* homologue (40); our sequencing results demonstrated that this is also true for *M. haemophilum* (Mh0166 and Mh3510), which occupies a somewhat similar *in vivo* niche. These conserved Nramp homologues are candidate iron uptake factors.

Iron uptake in bacteria is both critical and complex, characterized by the presence of multiple transport systems which may be utilized under different environmental conditions (77). In addition to the systems described above, it is likely that *M. haemophilum* encodes additional gene products involved in iron uptake. For instance, *M. haemophilum* encodes a locus (Mh0534–Mh0536) with homology to ATP-binding cassette (ABC) transport systems of the iron/siderophore/heme/vitamin B₁₂ type (78), including putative permease (Mh0536) and ATP-binding

(Mh0535) components as well as a putative substrate binding protein (Mh0534) homologous to proteins that play roles in iron uptake in other bacteria. Interestingly, this locus is absent in both *M. tuberculosis* and *M. leprae*. Future studies examining growth in the presence of ferrous iron and transcriptional responses of *M. haemophilum* under iron-replete versus iron-limited conditions and aerobic versus hypoxic conditions may help clarify the contributions of the gene products described above and identify additional genes involved in novel iron uptake pathways. Ultimately, it may also be informative to compare *in vitro* gene expression profiles to those obtained during intracellular and *in vivo* growth, to help elucidate mechanisms of iron acquisition in the context of infection.

Evolutionary relationships of *M. haemophilum*. Previous phylogenetic analyses based on limited available sequence data, such as *rpoB* gene comparisons, have suggested a close evolutionary relationship between *M. haemophilum* and *M. leprae* (79, 80). Our complete genome sequence data confirm the closeness of this relationship. A phylogenetic tree constructed by whole-chromosome comparison to 14 selected mycobacterial genomes using the BLAST algorithm revealed the closest neighbors to *M. haemophilum* DSM 44634/ATCC 29548 to be the *M. leprae* strains TN and B4923 and the recently identified *M. lepromatosis* (Fig. 6). This is also consistent with the genetic similarities detailed above and with analyses of fatty acid compositions and phenolic glycolipid contents of the organisms (81–83). However, at ~4.23 Mb, the genome of *M. haemophilum* is substantially larger than the ~3.27-Mb genomes of *M. leprae* and *M. lepromatosis*. The latter have both undergone extensive pseudogenization, of about approximately 50% of the genome (40, 42), while for *M. haemophilum* pseudogenes account for only ~7% of the total (NCBI Prokaryotic Genome Annotation Pipeline) (see Table S1 in the supplemental material). This suggests that the described reductive evolution of *M. leprae* and *M. lepromatosis* was not shared with the




FIG 6 Phylogenetic tree of selected mycobacterial species. A phylogenetic tree was constructed for 15 mycobacterial genomes, including *M. haemophilum*, and one outgroup genome as described in Materials and Methods. The scale (0.025) indicates substitutions per aligned position.

common ancestor, but instead began after divergence of *M. haemophilum* from the other two species.

Expression of foreign genes in *M. haemophilum*. Exploiting the genome sequence of and developing *M. haemophilum* into a model system could expand our understanding of its pathophysiology and allow new insights into *M. leprae*, which cannot be cultivated *in vitro*. Therefore, we explored whether we could transform *M. haemophilum* by electroporation, using protocols established for other slow-growing mycobacteria. Transformations with “empty vector” plasmid DNAs demonstrated abundant recovery of colonies when we used 100 $\mu\text{g/ml}$ kanamycin (for pMV261-kan and pMV361-kan) or 100 $\mu\text{g/ml}$ hygromycin (for pMV361-hyg) as selection agents (Fig. 7A). The no-DNA control transformations yielded no colonies at ~ 3 weeks of incubation, although with extended incubation small colonies appeared on the kanamycin-supplemented plates, indicating that higher antibiotic concentrations may be preferable. We noted the *attB* site (integration site for the pMV361 vectors) of *M. haemophilum* was identical to that of *M. smegmatis*. Integration of pMV361-kan and pMV361-hyg was confirmed by PCR across the *attB* locus and sequencing of products (data not shown). We also transformed *M. haemophilum* with an episomal plasmid expressing the tdTomato fluorescent protein under control of the *M. marinum* G13 promoter, a strong constitutive mycobacterial promoter that yields high expression levels (84). We found tdTomato to be very highly expressed, as indicated by the intense pink color of the colonies, which deepened further with extended incubation (Fig. 7A). Fluorescence of transformants was confirmed by microscopy (Fig. 7B), revealing a characteristic mycobacterial cording. These data provide the first demonstration that *M. haemophilum* can be genetically manipulated with molecular tools established for other mycobacterial species and establish a foundation upon which the sequence data obtained here can be exploited to study this unique human pathogen.

Conclusions. Fundamental to understanding *M. haemophilum* as a pathogen are defining the basis for its unique growth requirements and its relationships to other mycobacteria. Our sequence and experimental data provide insight into the requirement of *M. haemophilum* for specific iron supplements, which may contribute to its modest virulence in immunocompetent individuals. The sequence data provided here may also facilitate diagnostics. Current molecular diagnostic approaches for detection of *M. haemophilum* in clinical samples utilize PCR-based methods (85, 86) and rely on very limited sequence information. Because there may be genetic diversity among *M. haemophilum* isolates from different geographic areas (87–89), diag-

nostics might be improved by designing additional PCR-based, hybridization-based, and antigen-based tests for *M. haemophilum* by using information derived from the complete genome sequence. This information may also enable improved epidemiological and environmental testing, expanding the molecular tools




FIG 7 Successful transformation of *M. haemophilum*. (A) *M. haemophilum* was transformed with an integrating vector conferring hygromycin resistance (pMV361-hyg), an episomal vector conferring kanamycin resistance (pMV261-kan), an integrating vector conferring kanamycin resistance (pMV361-kan), or an episomal vector conferring kanamycin resistance and expressing the red fluorescent protein tdTomato from the *M. marinum* G13 promoter (pYUB1169). Colonies were photographed after 24 days of incubation at 30°C, while colonies harboring the tdTomato-expressing construct were photographed again at 33 days postincubation, to demonstrate intensification of the pink color. No-DNA controls demonstrating sensitivity of *M. haemophilum* to kanamycin and hygromycin at the indicated concentrations are also shown. In addition to antibiotic supplements, all plates also contained 100 μM hemin. (B) *M. haemophilum* transformed with the tdTomato fluoresce red. Images were obtained with a Nikon Eclipse TiE microscope using a CFI Plan Apo VC 100 \times /1.40 numerical aperture objective and a BrightLine Ex56240 filter set. The fluorescent image is shown on the left and a differential interference contrast image is on the right.

available to evaluate diversity. Our findings also demonstrate a close genetic relationship between *M. haemophilum* and *M. leprae*, the latter an important human pathogen that cannot be propagated *in vitro*. The successful transformation of *M. haemophilum* coupled with the genomic sequence will facilitate studies to elucidate the features that contribute to the pathogenic properties of *M. haemophilum* and allow its use as a surrogate to functionally characterize gene products uniquely shared by *M. haemophilum* and *M. leprae*.

MATERIALS AND METHODS

Bacterial strains. The *Mycobacterium haemophilum* type strain (DSM 44634; ATCC 29548) was cultured at 30°C in Middlebrook 7H9 broth supplemented with 0.2% glycerol, 10% OADC enrichment (Becton, Dickinson), 0.05% tyloxapol or Tween 80, and 100 µM hemin (bovine [Sigma]; 7H9-hemin) or as described above. Comparative growth studies utilized mc²6230, a $\Delta RD1 \Delta panCD$ derivative of *M. tuberculosis* H37Rv which is approved for use in BSL2 facilities at the Albert Einstein College of Medicine (31), and an *mbtB* deletion mutant in the mc²6230 background (see Text S1 in the supplemental material for further details on our materials and methods). Media for growth of mc²6230 and mc²6230 $\Delta mbtB$ were supplemented with 24 µg/ml D-pantothenate (Sigma).

Genome sequencing, assembly, and annotation. Genomic DNA isolated from cultures of *M. haemophilum* by a cetyltrimethylammonium bromide-chloroform-based method (90) was sequenced by the Epigenomics Shared Facility (ESF) at the Albert Einstein College of Medicine, using MiSeq (Illumina), and at the Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, using PacBio methodologies. Details of genome sequencing, assembly, and annotation are provided in Text S1 in the supplemental material.

Phylogenetic analysis. A phylogenetic tree was constructed for 15 mycobacterial genomes, including that of *M. haemophilum* and one outgroup genome. Further details concerning our materials and methods are provided in Text S1 in the supplemental material.

Protocol for plating on various media types. *M. haemophilum* bacteria cultured in 7H9-hemin were pelleted by centrifugation and washed in phosphate-buffered saline (PBS) containing 0.05% tyloxapol or 0.05% Tween 80 (PBS-T), following which equal inocula were plated onto the various media being tested. Details are provided in the Text S1 in the supplemental material.

Transformation of *M. haemophilum*. *M. haemophilum* transformation was performed according to methods developed for *M. tuberculosis* (90), except *M. haemophilum* was grown at 30°C. See Text S1 in the supplemental material for details.

Examination of mycobactin and carboxymycobactin synthesis and secretion based on use of a radiolabeled precursor. *M. haemophilum* and strain mc²6230 were cultured in 7H9 medium without hemin in order to deplete iron stores, following which bacteria were transferred to iron-limited 7H9 medium (treated overnight with the iron chelator Chelex-100; details are provided in Text S1 in the supplemental material). Bacteria were inoculated at a starting optical density at 600 nm of 0.3 in 5 ml of medium in the presence of 1 µCi/ml [7-¹⁴C]salicylic acid (PerkinElmer) and grown with shaking for 20 days at 37°C for mc²6230 and at 30°C for *M. haemophilum*. For *M. haemophilum*, cultures were prepared in duplicate, one lacking iron sources and one containing 10 µM hemin. Siderophores were extracted according to the method of Wells et al. (50) (see Text S1 for further details regarding our materials and methods). Extracts from cell pellets and culture supernatants were resuspended in chloroform and spotted on TLC silica gel 60F₂₅₄ plates, with samples normalized based on equivalent radioactivity levels.

Nucleotide sequence accession numbers. Sequence data were deposited in the NCBI repository under BioProject PRJNA171821 (*Mycobacterium haemophilum* DSM 44634, ATCC 29548). The complete genome sequence is available under accession number CP011883. Short Illumina reads, Illumina mate-pair reads, Pacific Biosciences SMRT reads,

and Sanger sequencing information were deposited in the NCBI Sequence Read Archive (SRA) under accession numbers SRX1059681, SRX1059688, SRX1059690, and SRX1059710, respectively. Genome annotations were deposited on the RAST website (<http://rast.nmpdr.org/>) (91, 92), first under Genome ID 1202450.3 and later updated to begin the sequence at *dnaA*, under Genome ID 1202450.9. The *M. haemophilum* gene numbers referenced in the text are those assigned based on the RAST annotation, Genome ID 1202450.9.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01313-15/-/DCSupplemental>.

Text S1, DOCX file, 0.1 MB.

Table S1, DOCX file, 0.03 MB.

Table S2, DOCX file, 0.02 MB.

Table S3, DOCX file, 0.04 MB.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants AI26170 and AI098925 to W.R.J.

We thank David Reynolds, Director of the Genomics Core Facility at the Albert Einstein College of Medicine, for helpful discussions on genome finishing and Colin Ratledge for generously providing the *M. smegmatis* mycobactin.

REFERENCES

- Lindeboom JA, Bruijnesteijn van Coppenraet LES, van Soolingen D, Prins JM, Kuijper EJ. 2011. Clinical manifestations, diagnosis, and treatment of *Mycobacterium haemophilum* infections. *Clin Microbiol Rev* 24:701–717. <http://dx.doi.org/10.1128/CMR.00020-11>.
- Sompolinsky D, Lagziel A, Naveh D, Yankilevitz T. 1978. *Mycobacterium haemophilum* sp. nov., a new pathogen of humans. *Int J Syst Bacteriol* 28:67–75. <http://dx.doi.org/10.1099/00207713-28-1-67>.
- Sompolinsky D, Lagziel A, Rosenberg I. 1979. Further studies of a new pathogenic mycobacterium (*M. haemophilum* sp. nov.). *Can J Microbiol* 25:217–226. <http://dx.doi.org/10.1139/m79-033>.
- Davis BR, Brumbach J, Sanders WJ, Wolinsky E. 1982. Skin lesions caused by *Mycobacterium haemophilum*. *Ann Intern Med* 97:723–724. <http://dx.doi.org/10.7326/0003-4819-97-5-723>.
- Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. 1996. *Mycobacterium haemophilum*: microbiology and expanding clinical and geographic spectra of disease in humans. *Clin Microbiol Rev* 9:435–447.
- Fairhurst RM, Kubak BM, Pegues DA, Moriguchi JD, Han KF, Haley JC, Kobashigawa JA. 2002. *Mycobacterium haemophilum* infections in heart transplant recipients: case report and review of the literature. *Am J Transplant* 2:476–479. <http://dx.doi.org/10.1034/j.1600-6143.2002.20514.x>.
- Hirsch R, Miller S, Kazi S, Cate T, Reveille J. 1996. Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. *Semin Arthritis Rheum* 25:347–356. [http://dx.doi.org/10.1016/S0049-0172\(96\)80020-5](http://dx.doi.org/10.1016/S0049-0172(96)80020-5).
- White MH, Papadopoulos EB, Small TN, Kiehn TE, Armstrong D. 1995. *Mycobacterium haemophilum* infections in bone marrow transplant recipients. *J Transplant* 60:957–960.
- Elsayed S, Read R. 2006. *Mycobacterium haemophilum* osteomyelitis: case report and review of the literature. *BMC Infect Dis* 6:70. <http://dx.doi.org/10.1186/1471-2334-6-70>.
- Sogani J, Ivanidze J, Phillips CD. 2014. Chiasmitis caused by *Mycobacterium haemophilum* in an immunocompromised adult. *Clin Imaging* 38:727–729. <http://dx.doi.org/10.1016/j.clinimag.2014.02.012>.
- Ducharlet K, Murphy C, Tan S, Dwyer KM, Goodman D, Aboltins C, Daffy JR, Langham RG. 2014. Recurrent *Mycobacterium haemophilum* in a renal transplant recipient. *Nephrology* 19(Suppl 1):14–17. <http://dx.doi.org/10.1111/nep.12193>.
- Shah M, Sebt A, Kiehn T, Massarella S, Sepkowitz K. 2001. *Mycobacterium haemophilum* in immunocompromised patients. *Clin Infect Dis* 33:330–337. <http://dx.doi.org/10.1086/321894>.
- Copeland NK, Arora NS, Ferguson TM. 2013. *Mycobacterium haemophilum* masquerading as leprosy in a renal transplant patient. *Case Rep Dermatol Med* 2013:793127. <http://dx.doi.org/10.1155/2013/793127>.
- Ishii K, Ishii N, Nakanaga K, Nakano K, Saito I, Asahina A. 2015. *Mycobacterium haemophilum* infection with prominent facial manifes-

- tation mimicking leprosy. *J Dermatol* 42:992–995. <http://dx.doi.org/10.1111/1346-8138.12948>.
15. Dawson DJ, Blacklock ZM, Kane DW. 1981. *Mycobacterium haemophilum* causing lymphadenitis in an otherwise healthy child. *Med J Aust* 2:289–290.
 16. Minani TJC, Saubolle MA, Yu E, Sussland Z. 2010. *Mycobacterium haemophilum* as a novel etiology of cervical lymphadenitis in an otherwise healthy adult patient. *J Clin Microbiol* 48:2636–2639. <http://dx.doi.org/10.1128/JCM.00814-10>.
 17. Kelley CF, Armstrong WS, Eaton ME. 2011. Disseminated *Mycobacterium haemophilum* infection. *Lancet Infect Dis* 11:571–578. [http://dx.doi.org/10.1016/S1473-3099\(11\)70029-9](http://dx.doi.org/10.1016/S1473-3099(11)70029-9).
 18. Kiehn TE, White M. 1994. *Mycobacterium haemophilum*: an emerging pathogen. *Eur J Clin Microbiol Infect Dis* 13:925–931. <http://dx.doi.org/10.1007/BF02111493>.
 19. Kamboj M, Louie E, Kiehn T, Papanicolaou G, Glickman M, Sepkowitz K. 2008. *Mycobacterium haemophilum* infection after alemtuzumab treatment. *Emerg Infect Dis* 14:1821–1823. <http://dx.doi.org/10.3201/eid1411.071321>.
 20. Aslam A, Green RL, Motta L, Ghrew M, Griffiths CEM, Warren RB. 2013. Cutaneous *Mycobacterium haemophilum* infection in a patient receiving infliximab for psoriasis. *Br J Dermatol* 168:446–447. <http://dx.doi.org/10.1111/j.1365-2133.2012.11164.x>.
 21. Collins CS, Terrell C, Mueller P. 2013. Disseminated *Mycobacterium haemophilum* infection in a 72-year-old patient with rheumatoid arthritis on infliximab. *BMJ Case Rep* 2013:bcr2012008034. <http://dx.doi.org/10.1136/bcr-2012-008034>.
 22. Brissot E, Gomez A, Aline-Fardin A, Lalande V, Lapusan S, Isnard F, Legrand O, Meynard J, Rubio M, Mohty M. 2014. Report of disseminated *Mycobacterium haemophilum* infection after double cord blood allo-SCT. *Bone Marrow Transplant* 49:1347–1348. <http://dx.doi.org/10.1038/bmt.2014.144>.
 23. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard M24-A2, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
 24. Barr LK, Sharer LR, Khadka Kunwar E, Kapila R, Zaki SR, Drew CP, Bhatnagar J, Liu JK, Chew D. 2015. Intraventricular granulomatous mass associated with *Mycobacterium haemophilum*: a rare central nervous system manifestation in a patient with human immunodeficiency virus infection. *J Clin Neurosci* 22:1057–1060. <http://dx.doi.org/10.1016/j.jocn.2014.11.036>.
 25. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr., Winthrop K, ATSDM Subcommittee, American Thoracic Society—Infectious Diseases Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 175:367–416. <http://dx.doi.org/10.1164/rccm.200604-571ST>.
 26. Sampaio JLM, Alves VAF, Leão SC, De Magalhaes V, Martino MDV, Mendes CMF, Misiara ACdO, Miyashiro K, Pasternak J, Rodrigues E, Rozenbaum R, Filho CAS, Teixeira SRM, Xavier AC, Figueiredo MS, Leite JPG. 2002. *Mycobacterium haemophilum*: emerging or underdiagnosed in Brazil? *Emerg Infect Dis* 8:1359–1360. <http://dx.doi.org/10.3201/eid0811.020492>.
 27. Vadney FS, Hawkins JE. 1985. Evaluation of a simple method for growing *Mycobacterium haemophilum*. *J Clin Microbiol* 22:884–885.
 28. Dawson DJ, Jennis F. 1980. *Mycobacteria* with a growth requirement for ferric ammonium citrate, identified as *Mycobacterium haemophilum*. *J Clin Microbiol* 11:190–192.
 29. Walder BK, Jeremy D, Charlesworth JA, Macdonald GJ, Pussell BA, Robertson MR. 1976. The skin and immunosuppression. *Australas J Dermatol* 17:94–97. <http://dx.doi.org/10.1111/j.1440-0960.1976.tb00798.x>.
 30. Jain P, Hartman TE, Eisenberg N, O'Donnell MR, Kriakov J, Govenor K, Makume M, Thaler DS, Hatfull GF, Sturm AW, Larsen MH, Moodley P, Jacobs WR, Jr. 2012. Phi(2)GFP10, a high-intensity fluorophore, enables detection and rapid drug susceptibility testing of *Mycobacterium tuberculosis* directly from sputum samples. *J Clin Microbiol* 50:1362–1369. <http://dx.doi.org/10.1128/JCM.06192-11>.
 31. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, Chen M, Kim J, Porcelli SA, Chan J, Morris SL, Jacobs WR, Jr. 2006. *Mycobacterium tuberculosis* ΔRD1 ΔpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. *Vaccine* 24:6309–6320. <http://dx.doi.org/10.1016/j.vaccine.2006.05.097>.
 32. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry CE, III. 2000. The salicylate-derived mycobactin siderophores of *Mycobacterium tuberculosis* are essential for growth in macrophages. *Proc Natl Acad Sci U S A* 97:1252–1257. <http://dx.doi.org/10.1073/pnas.97.3.1252>.
 33. Mezo A, Jennis F, McCarthy SW, Dawson DJ. 1979. Unusual mycobacteria in 5 cases of opportunistic infections. *Pathology* 11:377–384. <http://dx.doi.org/10.3109/00313027909059014>.
 34. Krithika R, Marathe U, Saxena P, Ansari MZ, Mohanty D, Gokhale RS. 2006. A genetic locus required for iron acquisition in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 103:2069–2074. <http://dx.doi.org/10.1073/pnas.0507924103>.
 35. Quadri LEN, Sello J, Keating TA, Weinreb PH, Walsh CT. 1998. Identification of a *Mycobacterium tuberculosis* gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. *Chem Biol* 5:631–645. [http://dx.doi.org/10.1016/S1074-5521\(98\)90291-5](http://dx.doi.org/10.1016/S1074-5521(98)90291-5).
 36. Chavadi SS, Stirrett KL, Edupuganti UR, Vergnolle O, Sadhanandan G, Marchiano E, Martin C, Qiu W-, Soll CE, Quadri LEN. 2011. Mutational and phylogenetic analyses of the mycobactin mbt gene cluster. *J Bacteriol* 193:5905–5913. <http://dx.doi.org/10.1128/JB.05811-11>.
 37. Felnagle EA, Barkei JJ, Park H, Podevels AM, McMahon MD, Drott DW, Thomas MG. 2010. MbtH-like proteins as integral components of bacterial nonribosomal peptide synthetases. *Bio Chem* 49:8815–8817. <http://dx.doi.org/10.1021/bi1012854>.
 38. Tatham E, Chavadi S, Mohandas P, Edupuganti UR, Angala SK, Chatterjee D, Quadri LEN. 2012. Production of mycobacterial cell wall glycopeptidolipids requires a member of the MbtH-like protein family. *BMC Microbiol* 12:118. <http://dx.doi.org/10.1186/1471-2180-12-118>.
 39. Harrison AJ, Yu M, Gardenborg T, Middleditch M, Ramsay RJ, Baker EN, Lott JS. 2006. The structure of MbtI from *Mycobacterium tuberculosis*, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase. *J Bacteriol* 188:6081–6091. <http://dx.doi.org/10.1128/JB.00338-06>.
 40. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honoré N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltham T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG. 2001. Massive gene decay in the leprosy bacillus. *Nature* 409:1007–1011. <http://dx.doi.org/10.1038/35059006>.
 41. Han XY, Seo Y, Sizer KC, Schoberle T, May GS, Spencer JS, Li W, Nair RG. 2008. A new mycobacterium species causing diffuse lepromatous leprosy. *Am J Clin Pathol* 130:856–864. <http://dx.doi.org/10.1309/AJCPP27FZZRRVMM>.
 42. Singh P, Benjak A, Schuenemann VJ, Herbig A, Avanzi C, Busso P, Nieselt K, Krause J, Vera-Cabrera L, Cole ST. 2015. Insight into the evolution and origin of leprosy bacilli from the genome sequence of *Mycobacterium lepromatosis*. *Proc Natl Acad Sci U S A* 112:4459–4464. <http://dx.doi.org/10.1073/pnas.1421504112>.
 43. Gold B, Rodriguez GM, Marras SAE, Pentecost M, Smith I. 2001. The *Mycobacterium tuberculosis* IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. *Mol Microbiol* 42:851–865. <http://dx.doi.org/10.1046/j.1365-2958.2001.02684.x>.
 44. Fiss EH, Yu S, Jacobs WR, Jr. 1994. Identification of genes involved in the sequestration of iron in mycobacteria: the ferric exochelin biosynthetic and uptake pathways. *Mol Microbiol* 14:557–569. <http://dx.doi.org/10.1111/j.1365-2958.1994.tb02189.x>.
 45. Yu S, Fiss E, Jacobs WR, Jr. 1998. Analysis of the exochelin locus in *Mycobacterium smegmatis*: biosynthesis genes have homology with genes of the peptide synthetase family. *J Bacteriol* 180:4676–4685.
 46. Zhu W, Arceneaux JEL, Beggs ML, Byers BR, Eisenach KD, Lundrigan MD. 1998. Exochelin genes in *Mycobacterium smegmatis*: identification of an ABC transporter and two non-ribosomal peptide synthetase genes. *Mol Microbiol* 29:629–639. <http://dx.doi.org/10.1046/j.1365-2958.1998.00961.x>.
 47. Farhana A, Kumar S, Rathore SS, Ghosh PC, Ehtesham NZ, Tyagi AK, Hasnain SE. 2008. Mechanistic insights into a novel exporter-importer system of *Mycobacterium tuberculosis* unravel its role in

- trafficking of iron. *PLoS One* 3:e2087. <http://dx.doi.org/10.1371/journal.pone.0002087>.
48. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I. 2002. *ideR*, an essential gene in mycobacterium tuberculosis: role of *IdeR* in iron-dependent gene expression, iron metabolism, and oxidative stress response. *Infect Immun* 70:3371–3381. <http://dx.doi.org/10.1128/IAI.70.7.3371-3381.2002>.
 49. Rodriguez GM, Smith I. 2006. Identification of an ABC transporter required for iron acquisition and virulence in *Mycobacterium tuberculosis*. *J Bacteriol* 188:424–430. <http://dx.doi.org/10.1128/JB.188.2.424-430.2006>.
 50. Wells RM, Jones CM, Xi Z, Speer A, Danilchanka O, Doornbos KS, Sun P, Wu F, Tian C, Niederweis M. 2013. Discovery of a siderophore export system essential for virulence of *Mycobacterium tuberculosis*. *PLoS Pathog* 9:e1003120. <http://dx.doi.org/10.1371/journal.ppat.1003120>.
 51. Deshayes C, Bach H, Euphrasie D, Attarian R, Coureuil M, Sougakoff W, Laval F, Av-Gay Y, Daffé M, Etienne G, Reyat J. 2010. *MmpS4* promotes glycopeptidolipids biosynthesis and export in *Mycobacterium smegmatis*. *Mol Microbiol* 78:989–1003. <http://dx.doi.org/10.1111/j.1365-2958.2010.07385.x>.
 52. Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, McMath LM, Iniguez A, Kimmey JM, Sawaya MR, Whitelegge JP, Horwitz MA, Goulding CW. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. *Proc Natl Acad Sci U S A* 108:5051–5056. <http://dx.doi.org/10.1073/pnas.1009516108>.
 53. Chim N, Iniguez A, Nguyen TQ, Goulding CW. 2010. Unusual diheme conformation of the heme-degrading protein from *Mycobacterium tuberculosis*. *J Mol Biol* 395:595–608. <http://dx.doi.org/10.1016/j.jmb.2009.11.025>.
 54. Simeone R, Bottai D, Frigui W, Majlessi L, Brosch R. 2015. ESX/type VII secretion systems of mycobacteria: insights into evolution, pathogenicity and protection. *Tuberculosis (Edinb)* doi:10.1016/j.tube.2015.02.019.
 55. Serafini A, Boldrin F, Palu G, Manganelli R. 2009. Characterization of a *Mycobacterium tuberculosis* ESX-3 conditional mutant: essentiality and rescue by iron and zinc. *J Bacteriol* 191:6340–6344. <http://dx.doi.org/10.1128/JB.00756-09>.
 56. Serafini A, Pisu D, Palu G, Rodriguez GM, Manganelli R. 2013. The ESX-3 secretion system is necessary for iron and zinc homeostasis in *Mycobacterium tuberculosis*. *PLoS One* 8:e78351. <http://dx.doi.org/10.1371/journal.pone.0078351>.
 57. Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng T, Siddiqi N, Fortune SM, Moody DB, Rubin EJ. 2009. Mycobacterial *Esx-3* is required for mycobactin-mediated iron acquisition. *Proc Natl Acad Sci U S A* 106:18792–18797. <http://dx.doi.org/10.1073/pnas.0900589106>.
 58. Maciag A, Dainese E, Rodriguez GM, Milano A, Provvedi R, Pasca MR, Smith I, Palu G, Riccardi G, Manganelli R. 2007. Global analysis of the *Mycobacterium tuberculosis* Zur (*FurB*) regulon. *J Bacteriol* 189:730–740. <http://dx.doi.org/10.1128/JB.01190-06>.
 59. Stoop EJM, Bitter W, van der Sar AM. 2012. Tubercle bacilli rely on a type VII army for pathogenicity. *Trends Microbiol* 20:477–484. <http://dx.doi.org/10.1016/j.tim.2012.07.001>.
 60. Houben ENG, Korotkov KV, Bitter W. 2014. Take five—type VII secretion systems of mycobacteria. *Biochim Biophys Acta* 1843:1707–1716. <http://dx.doi.org/10.1016/j.bbamcr.2013.11.003>.
 61. Ilghari D, Lightbody KL, Veverka V, Waters LC, Muskett FW, Renshaw PS, Carr MD. 2011. Solution structure of the *Mycobacterium tuberculosis* *EsxG*.*EsxH* complex: functional implications and comparisons with other *M. tuberculosis* *Esx* family complexes. *J Biol Chem* 286:29993–30002. <http://dx.doi.org/10.1074/jbc.M111.248732>.
 62. Bitter W, Houben ENG, Bottai D, Brodin P, Brown EJ, Cox JS, Derbyshire K, Fortune SM, Gao L, Liu J, Gey van Pittius NC, Pym AS, Rubin EJ, Sherman DR, Cole ST, Brosch R. 2009. Systematic genetic nomenclature for type VII secretion systems. *PLoS Pathog* 5:e1000507. <http://dx.doi.org/10.1371/journal.ppat.1000507>.
 63. Hantke K. 2003. Is the bacterial ferrous iron transporter *FeoB* a living fossil? *Trends Microbiol* 11:192–195. [http://dx.doi.org/10.1016/S0966-842X\(03\)00100-8](http://dx.doi.org/10.1016/S0966-842X(03)00100-8).
 64. Cartron ML, Maddocks S, Gillingham P, Craven CJ, Andrews SC. 2006. *Feo*: transport of ferrous iron into bacteria. *Biomaterials* 19:143–157. <http://dx.doi.org/10.1007/s10534-006-0003-2>.
 65. Hantke K. 1987. Ferrous iron transport mutants in *Escherichia coli* K12. *FEMS Microbiol Lett* 44:53–57. <http://dx.doi.org/10.1111/j.1574-6968.1987.tb02241.x>.
 66. Kammler M, Schon C, Hantke K. 1993. Characterization of the ferrous iron uptake system of *Escherichia coli*. *J Bacteriol* 175:6212–6219.
 67. Marlovits TC, Haase W, Herrmann C, Aller SG, Unger VM. 2002. The membrane protein *FeoB* contains an intramolecular G protein essential for *Fe(II)* uptake in bacteria. *Proc Natl Acad Sci U S A* 99:16243–16248. <http://dx.doi.org/10.1073/pnas.242338299>.
 68. Kim H, Lee H, Shin D. 2012. The *FeoA* protein is necessary for the *FeoB* transporter to import ferrous iron. *Biochem Biophys Res Commun* 423:733–738. <http://dx.doi.org/10.1016/j.bbrc.2012.06.027>.
 69. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. *Nature* 388:482–488. <http://dx.doi.org/10.1038/41343>.
 70. Supek F, Supekova L, Nelson H, Nelson N. 1996. A yeast manganese transporter related to the macrophage protein involved in conferring resistance to mycobacteria. *Proc Natl Acad Sci U S A* 93:5105–5110. <http://dx.doi.org/10.1073/pnas.93.10.5105>.
 71. Supek F, Supekova L, Nelson H, Nelson N. 1997. Function of metal-ion homeostasis in the cell division cycle, mitochondrial protein processing, sensitivity to mycobacterial infection and brain function. *J Exp Biol* 200:321–330.
 72. Makui H, Roig E, Cole ST, Helmann JD, Gros P, Cellier MFM. 2000. Identification of the *Escherichia coli* K-12 *Nramp* orthologue (*MntH*) as a selective divalent metal ion transporter. *Mol Microbiol* 35:1065–1078. <http://dx.doi.org/10.1046/j.1365-2958.2000.01774.x>.
 73. Kehres DG, Zaharik ML, Finlay BB, Maguire ME. 2000. The *NRAMP* proteins of *Salmonella typhimurium* and *Escherichia coli* are selective manganese transporters involved in the response to reactive oxygen. *Mol Microbiol* 36:1085–1100. <http://dx.doi.org/10.1046/j.1365-2958.2000.01922.x>.
 74. Agranoff D, Monahan IM, Mangan JA, Butcher PD, Krishna S. 1999. *Mycobacterium tuberculosis* expresses a novel pH-dependent divalent cation transporter belonging to the *Nramp* family. *J Exp Med* 190:717–724. <http://dx.doi.org/10.1084/jem.190.5.717>.
 75. Boechat N, Lagier-Roger B, Petit S, Bordat Y, Raugier J, Hance AJ, Gicquel B, Reyat J-. 2002. Disruption of the gene homologous to mammalian *Nramp1* in *Mycobacterium tuberculosis* does not affect virulence in mice. *Infect Immun* 70:4124–4131. <http://dx.doi.org/10.1128/IAI.70.8.4124-4131.2002>.
 76. Domenech P, Pym AS, Cellier M, Barry CE III, Cole ST. 2002. Inactivation of the *Mycobacterium tuberculosis* *Nramp* orthologue (*mntH*) does not affect virulence in a mouse model of tuberculosis. *FEMS Microbiol Lett* 207:81–86. <http://dx.doi.org/10.1111/j.1574-6968.2002.tb11032.x>.
 77. Braun V, Hantke K. 2011. Recent insights into iron import by bacteria. *Curr Opin Chem Biol* 15:328–334. <http://dx.doi.org/10.1016/j.cbpa.2011.01.005>.
 78. Köster W. 2001. ABC transporter-mediated uptake of iron, siderophores, heme and vitamin B12. *Res Microbiol* 152:291–301. [http://dx.doi.org/10.1016/S0923-2508\(01\)01200-1](http://dx.doi.org/10.1016/S0923-2508(01)01200-1).
 79. Han XY, Sizer KC, Thompson EJ, Kabanja J, Li J, Hu P, Gomez-Valero L, Silva FJ. 2009. Comparative sequence analysis of *Mycobacterium leprae* and the new leprosy-causing mycobacterium *lepromatium*. *J Bacteriol* 191:6067–6074. <http://dx.doi.org/10.1128/JB.00762-09>.
 80. Mignard S, Flandrois J-. 2008. A seven-gene, multilocus, genus-wide approach to the phylogeny of mycobacteria using supertrees. *Int J Syst Evol Microbiol* 58:1432–1441. <http://dx.doi.org/10.1099/ijs.0.65658-0>.
 81. Besra GS, McNeil M, Minnikin DE, Portaels F, Ridell M, Brennan PJ. 1991. Structural elucidation and antigenicity of a novel phenolic glycolipid antigen from *Mycobacterium haemophilum*. *Biochemistry* 30:7772–7777. <http://dx.doi.org/10.1021/bi00245a015>.
 82. Kusaka T, Izumi S. 1983. Gaschromatography of constitutive fatty acids in *Mycobacterium leprae*. *Microbiol Immunol* 27:409–414. <http://dx.doi.org/10.1111/j.1348-0421.1983.tb00599.x>.
 83. Portaels F, Dawson DJ, Larsson L, Rigouts L. 1993. Biochemical properties and fatty acid composition of *Mycobacterium haemophilum*: study of 16 isolates from Australian patients. *J Clin Microbiol* 31:26–30.
 84. Barker LP, Porcella SF, Wyatt RG, Small PLC. 1999. The *Mycobacterium marinum* *G13* promoter is a strong sigma 70-like promoter that is expressed in *Escherichia coli* and mycobacteria species. *FEMS Microbiol Lett* 175:79–85. <http://dx.doi.org/10.1111/j.1574-6968.1999.tb13604.x>.
 85. Buijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, Peeters MF, Claas ECJ, Kuijper EJ. 2004. Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. *J Clin Microbiol* 42:2644–2650. <http://dx.doi.org/10.1128/JCM.42.6.2644-2650.2004>.
 86. Wang SX, Sng LH, Leong HN, Tan BH. 2004. Direct identification of *Mycobacterium haemophilum* in skin lesions of immunocompromised

- patients by PCR-restriction endonuclease analysis. *J Clin Microbiol* 42: 3336–3338. <http://dx.doi.org/10.1128/JCM.42.7.3336-3338.2004>.
87. Bruijnesteijn van Coppenraet LES, Savelkoul PHM, Buffing N, van der Bijl MW, Woudenberg J, Lindeboom JA, Kiehn TE, Haverkort F, Samra Z, Kuijper EJ. 2009. Amplified fragment length polymorphism analysis of human clinical isolates of *Mycobacterium haemophilum* from different continents. *Clin Microbiol Infect* 15:924–930. <http://dx.doi.org/10.1111/j.1469-0691.2009.02798.x>.
 88. Kikuchi K, Bernard EM, Kiehn TE, Armstrong D, Riley LW. 1994. Restriction fragment length polymorphism analysis of clinical isolates of *Mycobacterium haemophilum*. *J Clin Microbiol* 32:1763–1767.
 89. Yakus MA, Straus WL. 1994. DNA polymorphisms detected in *Mycobacterium haemophilum* by pulsed-field gel electrophoresis. *J Clin Microbiol* 32:1083–1084.
 90. Larsen MH, Biermann K, Tandberg S, Hsu T, Jacobs WR. 2007. Genetic manipulation of *Mycobacterium tuberculosis*. *Curr Protoc Microbiol* 6:A: 10A.2:10A.2.1–10A.2.21.
 91. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. <http://dx.doi.org/10.1186/1471-2164-9-75>.
 92. Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, Edwards RA, Gerdes S, Parrello B, Shukla M, Vonstein V, Wattam AR, Xia F, Stevens R. 2014. The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). *Nucleic Acids Res* 42: D206–D214. <http://dx.doi.org/10.1093/nar/gkt1226>.